SAM
MYGN icon

Silvercrest Asset Management’s Myriad Genetics MYGN Stock Holding History

Silvercrest Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-183,206
Closed -$5.25M – 761
2019
Q3 		$5.25M Buy
+183,206
New +$5.34M 0.04% 326

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Silvercrest Asset Management's MYGN Position: Q4 2019 in Review

Silvercrest Asset Management sold out of Myriad Genetics (MYGN) in Q4 2019, closing a stake of 183,206 shares — an estimated $5.25M sold.

Silvercrest Asset Management first reported a position in MYGN in Q3 2019 and held it in 1 quarter. The position peaked at $5.25M in Q3 2019. 227 funds tracked by Wall St. Rank hold MYGN as of Q4 2019.

  • Silvercrest Asset Management reported no remaining Myriad Genetics position as of Q4 2019 after selling out during the quarter.
  • Silvercrest Asset Management sold 183,206 Myriad Genetics shares in Q4 2019, an estimated $5.25M.
  • Silvercrest Asset Management first reported a position in Myriad Genetics in Q3 2019 and held it in 1 quarter.
  • Silvercrest Asset Management's Myriad Genetics position peaked at $5.25M in Q3 2019.
  • 227 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2019.

Based on Silvercrest Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.